STRO Stock Forecast: Sutro Biopharma, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Sutro Biopharma, Inc. is $49. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Sutro Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (86): Sales and profits are climbing, and climbing faster than before.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
STRO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on STRO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Barclays | Maintains | Overweight | $56 → $57 |
| 15 Oct 2026 | Wedbush | Reiterates | Outperform | $60 |
| 13 Aug 2026 | Citizens | Maintains | Market Outperform | $41 → $34 |
| 13 Aug 2026 | Wedbush | Reiterates | Outperform | $60 |
| 11 June 2026 | Truist Securities | Assumes | Buy | $50 |
| 28 May 2026 | Barclays | Initiates | Overweight | — |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | Leerink Partners | Maintains | Outperform | — |
| 15 May 2026 | Wedbush | Upgrade | Outperform | — |
| 30 Apr 2026 | Mizuho | Initiates | Outperform | — |
| 23 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 17 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 7 Apr 2026 | Leerink Partners | Initiates | Outperform | — |
| 25 Mar 2026 | Deutsche Bank | Maintains | Buy | — |
| 24 Mar 2026 | HC Wainwright & Co. | Upgrade | Buy | — |
| 24 Mar 2026 | Wells Fargo | Upgrade | Overweight | — |
| 20 Jan 2026 | Citizens | Upgrade | Market Outperform | — |
| 22 Dec 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 12 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 16 June 2025 | Piper Sandler | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for STRO.
This page is one stock. Monday covers all of them.
STRO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
STRO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Sutro Biopharma, Inc. returned +1.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
STRO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.2×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 34% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −37.2%
- Dividend yield
- —
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sutro Biopharma, Inc. has a market value of $142.8M and an enterprise value of $10.3M.
Revenue in the twelve months to 30 June 2026: $45.7M. The latest quarter shrank 84.6% year on year.
Net income over the same four quarters: −$180.6M, a −395.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$145.6M.
Sutro Biopharma, Inc. employs 129 people — $354K of revenue per employee.
Data provided by Twelve Data
STRO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at STRO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Sutro Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about STRO
What is the STRO stock price forecast for 2026-2027?
The median 12-month analyst price target for Sutro Biopharma, Inc. is $49, with estimates ranging from $10 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is STRO stock a buy right now?
Of the 14 analysts covering Sutro Biopharma, Inc., 13 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sutro Biopharma, Inc. 56 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank STRO?
As at 21 Nov 2026, Sutro Biopharma, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).
Will STRO stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts is $49, and Ticker Nerd's factor model ranks Sutro Biopharma, Inc. 56 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the STRO stock forecast for 2030?
No analyst covering Sutro Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $61 over the next 12 months.
How has STRO stock performed over the past year?
Sutro Biopharma, Inc. returned +1.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sutro Biopharma, Inc. do?
Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. The company designs and advances antibody-drug conjugates, including site-specific, single-payload, dual-payload, and immunostimulatory formats, using its proprietary XpressCF and XpressCF+ platforms.
About Sutro Biopharma, Inc.
Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. The company designs and advances antibody-drug conjugates, including site-specific, single-payload, dual-payload, and immunostimulatory formats, using its proprietary XpressCF and XpressCF+ platforms. These technologies support the discovery, development, and manufacture of biologic drug candidates intended for oncology and other immune-related diseases. Sutro Biopharma’s work centers on creating precisely engineered therapies for solid tumors and hematologic cancers, while also supporting collaborative research and development efforts with pharmaceutical partners. Headquartered in South San Francisco, California, Sutro Biopharma plays a specialized role in the biopharmaceutical market by combining protein engineering, drug conjugation, and therapeutic development within a single platform-driven approach.
CEO Ms. Jane Chung R.Ph. · 129 employees · United States · https://www.sutrobio.com